Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$86.55 USD

86.55
3,439,683

-1.04 (-1.19%)

Updated Nov 15, 2024 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand

BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.

Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts

Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.

QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down

QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.

Urmimala Biswas headshot

Medtronic Stock Moves Above 50-Day SMA: Should You Buy MDT?

Medtronic's (MDT) stock finally breaking above its 50-day SMA can be a piece of good news for investors, signaling an uptrend.

Are Options Traders Betting on a Big Move in Boston Scientific (BSX) Stock?

Investors need to pay close attention to Boston Scientific (BSX) stock based on the movements in the options market lately.

Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales

Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.

Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised

Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Boston Scientific (BSX) Rides on Global Growth, Buyouts

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y

Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

GE HealthCare (GEHC) Q2 Earnings Beat Estimates, Net Margin Up

GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.

DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y

DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.

Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up

Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company???s transformational plans continue to benefit its operating income.

Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise

Ecolab's (ECL) robust performance across the majority of its segments drives its second-quarter sales amid business challenges.

Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised

Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.

Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up

Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.

3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.

Alphatec's (ATEC) New EOS Insight System to Boost Spine Care

Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise

Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.

Veeva Systems' (VEEV) Vault EDC to Boost Vita Global's Workflow

Veeva Systems' (VEEV) Vault EDC is likely to aid the CRO in delivering a better experience to patients, research sites and sponsors.

PacBio's (PACB) Revio System to Boost Novogene's German Lab

PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.

Boston Scientific (BSX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences

Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.